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The molecular mechanisms by which advanced cases of
cutaneous T cell lymphoma (CTCL) (mycosis fungoides/
Sezary syndrome) undergo large cell transformation
(LCT) and develop the morphologic appearance of a
large cell lymphoma, are undefined. We used immuno-
histochemical analysis and polymerase chain reaction/
single strand conformational polymorphism to examine
whether p53 mutations are associated with disease pro-
gression and LCT in CTCL. p53 protein immunohisto-
chemistry was performed on 37 paraffin embedded
biopsies from 27 patients with CTCL; LCT was present
in 15 biopsies. Overexpression of p53 protein was found
in 11 of 37 CTCL biopsies including 10 of 15 biopsies
(67%) with LCT in which p53 staining was predominantly
seen in large transformed cells. In contrast, p53 immuno-
staining was found in only one of 22 CTCL biopsies
Cutaneous T cell lymphoma (CTCL) (mycosis fungoides/Sezary syndrome) is a clonal malignancy of helper(CD41) T lymphocytes (T cells) usually first detectedin the skin. As the disease advances, lymph nodes,blood, and visceral organs are infiltrated with malignant
T cells (Greer et al, 1993). In 20–50% of advanced cases (Salhany et al,
1988; Cerroni et al, 1992), the malignant T cell clone undergoes
cytologic transformation (Salhany et al, 1988; Wood et al, 1993; Wolfe
et al, 1995). This large cell transformation (LCT) is characterized by
pleomorphic, large cells with prominent nucleoli resulting in the
morphologic appearance of a large cell lymphoma (Salhany et al, 1988;
Cerroni et al, 1992). Associated with this morphologic change is an
abrupt increase in the clinical aggressiveness of the malignancy with a
survival measured in months rather than years (Dmitrovsky et al, 1987;
Salhany et al, 1988).
The development of LCT in CTCL may be analogous to the
histologic transformation of low-grade follicular lymphoma to an
aggressive intermediate grade diffuse large cell lymphoma (Yunis et al,
1987), where p53 protein overexpression and p53 gene mutations are
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without LCT (p , 0.0004). Serial biopsies revealed
acquisition of p53 expression following LCT in two
patients in whom initial diagnostic biopsies without LCT
were p53 negative by immunostaining. All p53 protein
positive biopsies were from advanced lesions (cutaneous
tumors or extracutaneous sites); none of 12 patch/plaque
stage CTCL biopsies demonstrated p53 staining. Poly-
merase chain reaction/single strand conformational poly-
morphism and sequencing analysis of p53 exons 4–8 was
performed in 11 cases where frozen tissue was available.
No mutations were detected in six cases positive for p53
protein expression. These results suggest overexpression
of p53 protein in LCT and disease progression of CTCL
by a mechanism other than p53 gene mutation, in most
cases. Key words: mycosis fungoides/p53 gene mutations/Sezary
syndrome. J Invest Dermatol 110:767–770, 1998
present in 80% of the cases with histologic transformation to diffuse
large cell lymphoma, but not in cases without histologic transformation
(Lo Coco et al, 1993; Sander et al, 1993). Involvement of p53 gene
mutations also are involved in disease progression of other lymphomas
(Adamson et al, 1995; Li et al, 1995). In this study, we investigated
whether p53 mutations and p53 protein expression are involved in the
progression of CTCL to LCT.
MATERIALS AND METHODS
Cases studied The Institutional Review Boards at the University of Pennsyl-
vania Medical Center and the Philadelphia Veterans Affairs Medical Center
approved the use of excess diagnostic materials for these studies. Hematoxylin
and eosin stained slides were reviewed to confirm the diagnosis of CTCL
(mycosis fungoides/Sezary syndrome) (Greer et al, 1993). Biopsies were obtained
at an initial diagnosis prior to therapy, or during the course of standard topical
and/or systemic therapies. Large cell transformation (LCT) was defined as .50%
large transformed lymphocytes (Fig 1A), a modification of our initial definition
(Salhany et al, 1988) updated to conform to the current definition of large cell
lymphoma in the revised European–American lymphoma (REAL) classification
(Harris et al, 1994). A total of 37 archival specimens from 27 patients were
analyzed. Eight patients had two biopsies from different tissues or time points;
one patient had three different biopsies analyzed (Table I). There were 22
CTCL biopsies without LCT [16 skin (six patch, eight plaques, two tumors),
five lymph nodes, one lung biopsy] and 15 CTCL biopsies with LCT (five
skin tumors, eight lymph nodes, one lung, one bone marrow).
Immunohistochemical analysis Immunohistochemical analysis was per-
formed using a monoclonal antibody, DO-7 (DAKO, Carpinteria, CA), that
detects both mutant and wild-type p53 protein. Sections were incubated for
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Figure 1. LCT in cutaneous T cell lymphoma (case 26). (A) The lymph
node effaced by sheets of large transformed cells (immunoblasts) with prominent
nucleoli (hematoxylin and eosin). (B) Nuclear staining of p53 protein within
many large transformed cells (arrows). The intensity of staining varies from very
dark nuclei to nuclear staining that is only slightly increased above the
hematoxylin counterstain (diaminobenzidine-hematoxylin, DO-7 p53 antibody;
scale bars, 20 µm).
10 min in a 95°C water bath with an antigen retrieval system (BioGenex
KH0875K, San Ramon, CA) and then immunostained using a 1:10 dilution
of DO-7 and a standard avidin-biotin-horseradish peroxidase technique (Strauss
et al, 1995). Expression of p53 in cerebriform and large transformed cells was
scored as negative (,5%), 11 (5–20%), 21 (21–50%), or 31 (.50%).
Polymerase chain reaction (PCR)/single strand conformation poly-
morphism (SSCP) analysis Genomic DNA were extracted from snap
frozen samples (Brice et al, 1989). Extracted DNA were screened by the PCR/
SSCP method with the same oligonucleotide primers and conditions for p53
exons 4–8 as previously described (Mitsudomi et al, 1992; Felix et al, 1994).
DNA sequencing Samples with band shift patterns on SSCP were evaluated
by sequencing individual genomic subclones. Fresh aliquots of genomic DNA
were amplified with PCR primers encompassing the region of the band shift.
The PCR products were subcloned into TA vector (Invitrogen, San Diego,
CA) and six to eight individual genomic subclones were sequenced by the
dideoxynucleotide method (Sanger et al, 1977).
Statistical analysis Two by two comparisons were made between cases with
and without LCT and cases with and without p53 nuclear staining by the
Fisher exact test using StatView II- software.
RESULTS
Immunohistochemistry analysis reveals association of p53 nuc-
lear staining with LCT p53 immunohistochemistry was performed
on 37 biopsies: 15 biopsies from 10 patients with CTCL showing LCT
and 22 biopsies from 17 patients without LCT. The p53 immunostaining
results are summarized in Table I. p53 protein expression was detected
in the nucleus in 11 of 37 biopsies; all with advanced stage cutaneous
Table I. Immunohistochemistry and PCR/SSCP data
summary
Tissue p53
Patient Diagnosisa (biopsy date) stainingb PCR/SSCPc
1 CTCL (MF) Skin patch – ND
2 CTCL (MF) Skin patch – ND
3 CTCL (MF) Skin patch – –
4 CTCL (MF) Skin patch – –
5 CTCL (MF) Skin patch – ND
CTCL (MF) Skin plaque – ND
6 CTCL (MF) Skin patch – ND
CTCL (MF) Skin plaque – ND
7 CTCL (MF) Skin plaque – –
8 CTCL (MF) Skin plaque – ND
9 CTCL (MF) Skin plaque – ND
10 CTCL (MF) Skin plaque – ND
11 CTCL (SS) Lymph node – ND
12 CTCL (MF) Lymph node – –
13 CTCL (MF) Lymph node – –
14 CTCL (MF) Lymph node – ND
15 CTCL (SS) Lymph node – ND
16 CTCL (MF) Skin tumor 11 ND
17 CTCL (MF) Skin tumor – –
18 CTCL (SS) Lung – ND
CTCL (SS)–LCT Bone marrow 21 ND
19 CTCL (SS)-LCT Lymph node – ND
20 CTCL (SS) Skin plaque (1987) – ND
CTCL (SS)–LCT Skin tumor (1993) 11 –
CTCL (SS)–LCT Skin tumor (1994) 11 –
21 CTCL (MF) Skin plaque – –
CTCL (MF)–LCT Lymph node 21 –
22 CTCL (MF)-LCT Skin tumor – ND
CTCL (MF)-LCT Lymph node – ND
23 CTCL (MF)-LCT Skin tumor 21 ND
CTCL (MF)–LCT Lymph node 21 ND
24 CTCL (MF)-LCT Lymph node 31 1*
25 CTCL (MF)-LCT Skin tumor – ND
CTCL (MF)–LCT Lymph node 11 –
26 CTCL (SS)-LCT Lymph node 31 1*
27 CTCL (SS)-LCT Lung 11 ND
CTCL (SS)-LCT Lymph node – ND
aCTCL, cutaneous T cell lymphoma (MF, mycosis fungoides; SS, Sezary syndrome);
LCT, large cell transformation.
b31, .50% staining; 21, 21–50% staining; 11, 5–20% staining; –, ,5% staining.
c –, normal migration pattern; 1, aberrant migration pattern; *polymorphisms in exon
4 by DNA sequencing.
and extracutaneous disease. Nuclear p53 protein was detected in large
transformed lymphoma cells in 10 of 15 CTCL biopsies with LCT
(Fig 1) and in small cerebriform cells in one of 22 CTCL biopsies
without LCT. p53 nuclear staining in samples demonstrating LCT was
statistically significant (p , 0.0004, Fisher exact test) compared with
absence in those without LCT. The intensity of p53 protein expression
was variable. Two cases had 31 p53 staining, four cases were scored
21, five cases were 11. One cutaneous tumor without LCT and with
rare (,5%) p531 cerebriform cells was scored as negative. Ten of 11
p53 positive biopsies had LCT. None of the 12 patch/plaque biopsies
(from 10 patients with early stage disease) showed p53 immunostaining.
Each of the biopsies scored 21 or above showed LCT. In two patients
(patients 20 and 21) with serial biopsies, p53 protein expression
was present following LCT but not in the initial diagnostic patch/
plaque stage.
SSCP/DNA sequencing analysis does not reveal p53 gene
mutations Thirteen CTCL biopsy specimens from 11 patients were
subjected to SSCP analysis of exon 4 to exon 8 of the p53 gene. Six
biopsies stained positive for p53 protein (three cases were 11, one
case was 21, and two cases were 31) and seven biopsies were negative
for p53 protein staining. Band shifts were shown by SSCP (Fig 2) in
both cases with 31 p53 immunostaining and none from those with
negative p53 staining or other cases with less intensive staining (Table I).
The results of DNA sequencing of the two cases showing SSCP pattern
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Figure 2. PCR/SSCP and direct sequencing demonstrates
polymorphisms in exon 4. (a) PCR/SSCP of p53 exon 4: lane 1, case 24,
skin; lane 2, case 24, lymph node; lane 3, case 26, lymph node; lanes 4 and 5,
controls, normal human peripheral blood lymphocytes (without p53 exon 4
polymorphisms); aberrant bands (arrowheads) are indicated. (b) DNA sequencing
of p53 exon 4 in case 24, showing polymorphic (top) and wild-type (bottom)
nucleotide sequences indicated by arrows.
differences demonstrated nucleotide differences in exon 4 at codon 36
(CCG→CCA) (Fig 2) or codon 72 (CGC→CCC) (data not shown),
consistent with previously described p53 gene polymorphisms (Ara
et al, 1990; Felix et al, 1994). Therefore, no point mutations from
exons 4–8 of the p53 gene were identified in the six cases with p53
positive immunostaining that we analyzed.
DISCUSSION
We have demonstrated that abnormal p53 protein expression in
CTCL is significantly associated with advanced stage cutaneous and
extracutaneous disease. In particular, nuclear p53 expression was
detected in 67% of biopsies (10 of 15) with LCT compared with only
one of 22 biopsies without LCT (p , 0.0004). Moreover, analysis of
serial biopsies revealed detectable nuclear p53 immunostaining follow-
ing progression to LCT in two cases where diagnostic CTCL specimens
prior to LCT failed to demonstrate p53 immunostaining. Previous
immunohistochemistry studies have found p53 protein expression in
,10% of CTCL (mycosis fungoides/Sezary symdrome) cases, but
nearly all p53 protein positive cases were found at the more advanced
stages of disease, predominantly at the tumor stage (Kanavaros et al,
1994; de Misa et al, 1995; Garatti et al, 1995; Lauritzen et al, 1995;
McGregor et al, 1995; Neri et al, 1995). The recent study of Lauritzen
et al found positive p53 immunostaining in 47% (eight of 17) of CTCL
with LCT (Lauritzen et al, 1995).
Our data suggest that the p53 involvement in the progression of
CTCL to LCT may differ from other hematologic cancer models,
such as follicular lymphoma progression to diffuse large cell lymphoma
(Sander et al, 1993; Imamura et al, 1994). In follicular lymphoma, the
appearance of p53 positive immunostaining cells could be detected in
pre-transformation biopsies, although at a much lower frequency than
post-transformation. An increase in the number of p53 positively
staining cells was also documented in the progression of follicular
lymphoma to diffuse large cell lymphoma over time (Lo Coco et al,
1993; Sander et al, 1993). Therefore, overexpression of p53 protein in
follicular lymphoma may play a role in both initial pathogenesis and
disease progression. In contrast, no detectable p53 protein was found
in the early stages of CTCL and serial biopsies demonstrated p53
overexpression only in post-LCT specimens and not in earlier pre-
transformation biopsies.
The pattern of p53 immunostaining without p53 mutations in LCT
progression is more like CD30 (Ki-1) positive anaplastic large cell
lymphoma (ALCL) that have morphologic and immunophenotypic
similarities to LCT-CTCL (Salhany et al, 1988; Li et al, 1997). Cesarman
et al (1993) reported strong nuclear p53 immunostaining in 12 of 15
cases of ALCL, but mutations were rare. The failure to detect p53
gene mutations in the cases with positive p53 protein immunostaining
that we analyzed in this study is unlikely due to the sensitivity of the
method. p53 mutation analysis by PCR/SSCP has been shown to
have a detection sensitivity of one in 16 cells (Mitsudomi et al, 1992).
We analyzed p53 exons 4–8 by SSCP analysis, the region where over
90% of the p53 gene point mutations occur in other cancers (Greenblatt
et al, 1994). In addition, p53 gene mutation in CTCL reported by
Marks et al occurred in exons 4 and 6 and p53 gene mutation in
follicular lymphoma and diffuse large cell lymphoma have been detected
in exons 5–8 (Sander et al, 1993; Marks et al, 1996). The absence of
mutations in the cases in this study is consistent with nuclear accumula-
tion of wild-type p53 in LCT-CTCL.
Immunohistochemical detection of p53 nuclear protein accumulation
was initially correlated with p53 gene mutations resulting in accumula-
tion of mutant p53 protein that has a longer half-life than wild-
type p53 protein (Vogelstein and Kinzier, 1992). Subsequent reports,
however, have documented both nuclear and cytoplasmic accumulation
of wild-type p53 protein through interactions with viral or host
proteins (Oliner et al, 1992; Lane, 1994; Moll et al, 1996; Lutzker and
Levine, 1996). Human sarcomas with mdm-2 gene amplification and
increased mdm-2 protein show wild-type p53 protein overexpression
(Oliner et al, 1992; Landers et al, 1994). Recently, Marks et al have
demonstrated overexpression of mdm-2 protein in advanced CTCL
(Marks et al, 1996). Overexpression of mdm-2 protein by peripheral
blood mononuclear cells from four of 18 patients with Sezary syndrome
was detected by western blot analysis; however, mdm-2 protein
overexpression was independent of p53 status. Interestingly, p53 gene
mutations were detected in two of 18 cases.
Thus, p53 gene mutations are rare in CTCL and CTCL-LCT.
Nonetheless, p53 protein accumulation in advanced stage CTCL and
CTCL-LCT suggest that abnormalities in p53 protein expression or
function may play a role in LCT and disease progression in CTCL by
mechanisms other than p53 gene mutation, in most cases.
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